MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

2023 International Congress

August 27-31, 2023. Copenhagen, Denmark.

View by Title View Categories
Jump to:  View All • a b c d e f g h i j k l m n o p q r s [t] u v w x y z
  • T1 MRI reveals differential hippocampal atrophy in Lewy body disorders with and without Alzheimer’s copathology

    J. Cohen, J. Phillips, S. Das, E. Rhodes, K. Cousins, P. Yushkevich, D. Wolk, D. Weintraub, D. Irwin, C. Mcmillan (Philadelphia, USA)

  • Tai Chi training of people with Parkinson’s disease (PD) – neuropsychological and electrophysiological analyses

    U. Gschwandtner, K. Toloraia, M. Atanasova, TM. Al Tawil, S. Elsas, P. Fuhr (Basel, Switzerland)

  • Taking the driver’s seat on Parkinson’s care

    J. Benalcazar Silva (Melbourne, Australia)

  • Tardive dystonia manifesting in lid-opening apraxia, oromandibular dystonia, and laterocollis after long-term sulpiride use

    S. Brillman, T. Gongalore (Palo Alto, USA)

  • Targeted sequencing of regulatory regions shows potential SNVs affecting FXN gene expression in Friedreich’s ataxia patients

    V. Swarup, H. Singh, V. Kumar, D. Gupta, A. Ahuja, I. Singh, R. Rajan, A. Srivastava (New Delhi, India)

  • Targeting autophagy to identify novel modulators of Parkinson’s disease using midbrain organoids

    J. Jarazo, I. Rosety, C. Serra-Almeida, R. Marques, C. Saraiva, R. Davis, J. Schwamborn (Esch-sur-Alzette, Luxembourg)

  • Tau PET imaging in a patient with progressive supranuclear palsy-parkinsonism-a case report

    S. Su, Y. Weng, K. Lin, I. Hsiao, K. Huang, C. Lu (Taoyuan City, Taiwan)

  • Technological Approach to Phenotypical Characterization of Functional Movement Disorders

    A. Torquati, G. Fidenzi, LG. Santilio, AE. Elia, N. Golfré Andreasi, G. Devigili, R. Cilia, F. Cosignani, BNG. Conti, P. Amami, S. Piacentini, S. Prioni, R. Eleopra, LM. Romito (Limbiate, Italy)

  • Technological visuo-cognitive training in Parkinson’s disease: Preliminary findings from a pilot randomised controlled trial

    J. Das, G. Barry, R. Vitorio, R. Walker, C. Mcdonald, R. Morris, S. Stuart (Newcastle upom Tyne, United Kingdom)

  • Telehealth Follow-up for Cervical Dystonia Treated with Neurotoxin Injection

    K. Harper, S. Sharp, N. Jones, M. Turchan, M. Hacker, J. Meystedt, S. Ploucher, L. Schattinger, D. Makini, A. Terala, D. Charles (Nashville, USA)

  • Telemedicine and in-person encounters in a Huntington’s disease cohort: virtually the same

    E. Girouard, JF. Daneault, A. James-Palmer, S. Chouinard, A. Richard (Montréal, Canada)

  • Telemedicine challenges in the management of patients with Parkinson’s disease in Central Asia.

    A. Iliazova, E. Zhunusova, C. Shambetova (Bishkek, Kyrgyzstan)

  • Teleprogramming Reduces the Time Needed to Optimize DBS Therapy: Results from the ROAM-DBS study

    A. Gharabaghi, D. Weiss, S. Groppa, L. Lopez Manzanares, A. Schnitzler, R. Alvarez, L. Muñoz-Delgado, C. Luca, J. Karl, V. Marshall, L. Zhang, M. Soileau, B. Dalm, M. Feldman, S. Zauber, H. Lei, L. Luo, B. Walter, C. Wu (Tübingen, Germany)

  • TELO2 defect presenting with childhood-onset complex hyperkinetic MD

    M. Novelli, S. Galosi, R. Carrozzo, L. Travaglini, L. Pollini, C. Caputi, F. Pisani, V. Leuzzi (Rome, Italy)

  • TEP-PSP: preliminary results of a therapeutic education program in progressive supranuclear palsy

    A. Camara, C. Painous, M. Baixauli, J. Herrero, S. Pelaez, I. Martin, I. Quiñoa, C. Torregrosa, M. Carrasco, JC. Lopez Reyes, L. Maragall, Y. Compta (Barcelona, Spain)

  • Testing for alcohol responsivity in familial essential tremor

    C. Everlo, M. Tijssen, M. V.D. Stouwe (Groningen, Netherlands)

  • Testing gene-environment interaction in Parkinson’s disease (PD) using whole-genome sequencing of pesticide-exposed cohorts.

    S. Goldman, J. Kaye, M. Traglia, R. Swanson, L. Lima, S. Finkbeiner, C. Tanner (San Francisco, USA)

  • Testing the applicability of the dysarthria analyzer to detect levodopa effects on speech in a German cohort of people with Parkinson’s disease

    T. Thies, J. Schreen, H. Jergas, M. Barbe (Cologne, Germany)

  • Text entry as a digital outcome in Parkinson’s disease patients (TEXT-PD): results from two exploratory studies

    L. Azevedo Kauppila, A. Rodrigues, F. Pona Ferreira, M. Leitão, A. Santos, D. Branco, H. Nicolau, J. Ferreira, T. Guerreiro (Torres Vedras, Portugal)

  • The added value of accelerometric monitoring during thalamotomy

    A. Smid, M. Oterdoom, R. Pauwels, K. Tamasi, J. Elting, A. Absalom, T. van Laar, M. van Dijk, G. Drost (Groningen, Netherlands)

  • The association between compliance and the effects of home-based touchscreen training in Parkinson’s disease

    J. de Vleeschhauwer, E. Nackaerts, Y. Zhang, L. Janssens, W. Vandenberghe, A. Nieuwboer (Leuven, Belgium)

  • The association between perceived walking difficulties and gait speed in people with drug naïve/early PD

    SB. Jonasson, M. Lindh-Rengifo, E. Stomrud, O. Hansson, MH. Nilsson (Lund, Sweden)

  • The Blood-Brain Barrier Integrity and Prevalence of Intrathecal T Helper 17.1 Cells in Huntington´s Disease

    B. ásbjörnsdóttir, C. Musaeus, M. Hellem, T. Vinther-Jensen, L. Hjermind, A. Simonsen, M. von Essen, F. Sellebjerg, J. Nielsen (Copenhagen, Denmark)

  • The cause of death in Parkinson’s disease

    K. Kamada, K. Kino, T. Takata (Kagawa, Japan)

  • The changes in alpha-synuclein level and oscillatory activity of substantia nigra by nigral electrical stimulation

    T. Yamamoto, R. Sakakibara, T. Uchiyama, S. Kwabara (Chiba, Japan)

  • The characterization of Parkinson’s disease related nociplastic pain based on the classification system

    T. Tezuka, T. Nukariya, S. Okusa, Y. Nihei, J. Nakahara, M. Seki (Tokyo, Japan)

  • The Comorbidity and Comedication Profiles of Patients with Progressive Supranuclear Palsy in Two German, Multicenter Cohorts: A Systematic Cross-Sectional Analysis

    S. Greten, F. Wegner, O. Krause, J. Heck, GU. Höglinger, M. Klietz (Hannover, Germany)

  • The comparison of curcumin and naringenin effects on motor function in rotenone model of Parkinson’s disease

    S. Madiha (Karachi, Pakistan)

  • The comparison of vaccination rate, health impact, and confidence of COVID-19 vaccines between patients with Parkinson’s disease and healthy population: evidence from a large multicenter survey in China

    C. Han, Z. Zhao, J. Ma (Beijing, China)

  • The contribution of Brain Bank for Aging Research to pathomechanism of Parkinson’s disease

    S. Murayama, Y. Saito (Osaka, Japan)

  • The Critical Path for Parkinson’s Consortium approach to developing consensus recommendations for neuroimaging biomarkers appropriate for use in Parkinson’s disease drug development

    M. Muller, R. Comley, J. Eberling, H. Kazmi, T. Kustermann, P. Maguire, K. Marek, C. Mcginnity, M. Minchik, C. Parker, L. Passamonti, O. Rousset, D. Russell, C. Salinas, J. Seibyl, S. Sivakumaran, J. Stoessl, A. Strafella, D. Tosun-Turgut, Y. Wang, D. Stephenson, G. Pagano (Tucson, USA)

  • The crucial role of the visual system on the PISA syndrome in Parkinson’s disease

    A. Yoritaka, T. Hayashi, K. Fusegi, S. Nakayama, M. Ando, N. Hattori (Koshigaya, Saitama, Japan)

  • The development of a multiplex allele specific PCR to improve the diagnostic yield of NGS in the GBA gene screening

    C. Panteghini, C. Reale, I. Colangelo, M. Suerz, R. Cilia, R. Eleopra, B. Garavaglia, F. Invernizzi (Milano, Italy)

  • The diagnosis value of dopaminergic responsiveness of Parkinson’s disease: a systematic review and meta-analysis

    WY. Kou, HH. Cai, FT. Feng (beijiing, China)

  • The diagnostic utility of the new MDS criteria for multiple system atrophy: a retrospective autopsy cohort study

    H. Sekiya, S. Koga, A. Murakami, M. Kawazoe, N. Martin, R. Uitti, W. Cheshire, Z. Wszolek, D. Dickson (Jacksonville, USA)

  • The Dystonic Drive – A Systematic Review on Coherence Analysis in Dystonia

    S. Lagerweij, M. Smit, L. Centen, M. van Egmond, JW. Elting, M. Tijssen (Groningen, Netherlands)

  • The East London Parkinson Disease Project – preliminary results from a diverse population

    A. Zirra, KC. Dey, E. Camboe, T. Haque, A. Ben-Joseph, J. Kahan, D. Gallagher, C. Budu, B. Huxford, C. Simonet, A. Lees, CR. Marshall, AJ. Noyce (London, United Kingdom)

  • The effect of anti- Parkinson’s disease granules and probiotics on gastrointestinal motility in the mouse model of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine -induced Parkinson’s disease

    X. Zhao, J. Yang (Shanghai, China)

  • The effect of APOE ε4 on striatal vesicular monoamine transporter-2 density in Parkinson’s disease

    W. Li, R. Li, J. Lu (Beijing, China)

  • The effect of botulinum toxin on anxiety in cervical dystonia.

    D. Sugar, R. Patel, C. Comella, D. Gonzalez, G. Gray, G. Stebbins, A. Mahajan (Chicago, USA)

  • The effect of cathodal transcranial direct current stimulation in the treatment of Levodopa-Induced Dyskinesias in Parkinson’s Disease: a preliminary report.

    B. Angeloni, R. Di Iorio, F. Bove, P. Sanginario, C. Piano, A R. Bentivoglio, P. Calabresi (Rome, Italy)

  • The effect of continuous subcutaneous apomorphine infusion on vitamin B metabolites and plasma homocysteine in Parkinson’s disease patients

    O. Phokaewvarangkul, N. Kantachadvanich, R. Bhidayasiri (Bangkok, Thailand)

  • The effect of dopaminergic medication on force fluctuation in Parkinson’s disease

    B. Afsharipour, M. Schindle, F. Roy, F. Ba, M. Gorassini, T. Sankar (Edmonton, Canada)

  • The effect of exercise training on motor and non-motor symptoms in people with Essential Tremor; a feasibility pilot study

    H. Khalil, M. Nazzal, A. Al-Sharman, L. Samman, D. Al-Shorafat, K. El-Salem, H. Al Refa’I, S. Obeidat (Doha, Qatar)

  • The effect of intranasal insulin administration on motor and non-motor symptoms in Parkinson’s disease patients; a randomized double-blinded placebo-controlled clinical trial

    M. Salari, N. Valian, L. Mohaghegh Shalmani, R. Rashedi, H. Ashourizadeh, L. Dargahi (Tehran, Islamic Republic of Iran)

  • The effect of levodopa on the blood activity of calpains in patients with Parkinson’s disease

    Z. Muruzheva, M. Absalyamova, M. Karpenko (Saint-Petersburg, Russian Federation)

  • The effect of lumboperitoneal shunt surgery on patients with iNPH plus Parkinson’s disease

    T. Tsunemi, T. Shimada, A. Sakukrai, M. Nakajima, N. Hattori (Toyoo, Japan)

  • The effect of peptic ulcer disease on Parkinson’s disease

    T. Abali, AV. Karacan, S. Kibrit, MK. Yekedüz, EY. Unutmaz, T. Eminoglu, R. Yilmaz, MC. Akbostancı (Ankara, Turkey)

  • The effect of subthalamic deep brain stimulation on response inhibition and voluntary action control depend on connectivity of the volume of activated tissue with the prefrontal cortex

    J. Waldthaler, A. Sperlich, C. Stüssel, K. Steidel, L. Timmermann, D. Pedrosa (Marburg, Germany)

  • The effect of subthalamic therapeutic deep brain stimulation on pallidal and cortical activity in Parkinson’s disease

    F. Sarmento, J. Hernandez, T. de Araujo, J. Wong, D. Wang, P. Starr, C. de Hemptinne (Gainesville, USA)

  • The effect of taVNS on gait in advanced Parkinsons disease – a double blind, sham controlled motion sensors study in 30 patients

    V. van Midden, Z. Pirtošek, U. Simončič, M. Kojović (Ljubljana, Slovenia)

  • The effectiveness and usability of online rehabilitation for Parkinson’s Disease patients

    S. Okusa, H. Saegusa, K. Miyakawa, Y. Tsutsumi, S. Ishida, K. Nishikata, T. Nukariya, T. Tezuka, Y. Nihei, Y. Kitagawa, S. Kubo, N. Suzuki, J. Nakahara, M. Seki (Tokyo, Japan)

  • The Effects of Consecutive and Integrated Postural-Cognitive Training on Dual-task Walking in Parkinson’s Disease with Mild Cognitive Impairment: EEG Relative Power and Clinical Implication

    YA. Chen, CY. Huang, RM. Wu, CL. Chang (Taipei, Taiwan)

  • The effects of dopaminergic treatment on interhemispheric disinhibition and bradykinesia asymmetry in Parkinson’s disease

    M. de Riggi, G. Paparella, M. Bologna, D. Colella, A. Cannavacciuolo, A. de Biase, D. Birreci, D. Costa, A. Guerra, A. Berardelli (Rome, Italy)

  • The effects of mental imagery on balance, anxiety and quality of life of older people with early stage of dementia: Preliminary data

    C. Bouzineki, A. Christakou (Athens, Greece)

  • The Effects of Motor Imagery Therapy in the rehabilitation of patients with Parkinson’s Disease: A Systematic Review

    A. Ibrahim Abdelhamed, M. Abdeen, H. Elkhodary, A. Samir, A. El-Shazly, M. Zaghloul, A. Abdelmalek, E. Elbathesh, R. Salem, A. Mohamed, A. Ashour, M. Fahmy, H. Samy, M. Shafiek Saleh (Elfashn, Egypt)

  • The effects of one session of dry needling on vital capacity in people with Parkinson’s Disease

    A. Tahara, A. Gastaldi, A. Chinaglia, R. Monteiro, V. Tumas, P. Santiago (Ribeirão preto, Brazil)

  • The efficacy of dopamine agonists or monoamine oxidase type B inhibitors as monotherapy in patients with early Parkinson disease: A network meta-analysis

    CSC. Chuang (Changhua, Taiwan)

  • The efficacy of thalamic and pallidal deep brain stimulation rescue leads in dystonic tremor depends on the affected body region – a case series

    S. Paschen, J. Becktepe, M. Hobert, K. Zeuner, A. Helmers, D. Berg, G. Deuschl (Kiel, Germany)

  • The efficacy of transcutaneous tibial nerve stimulation for Parkinson’s urinary problems: A Systematic review

    A. Ibrahim Abdelhamed, A. Salah, M. Salama, S. Ezz, H. Samy, N. Karam, O. Hazem, H. Hossam, H. Ahmed, Y. Hamayel, M. Ramadan, M. Emad Fahmy, M. Shafiek Saleh (Elfashn, Egypt)

  • The Efficacy of Virtual Reality Interventions on Gait and Balance in Patients with Parkinson Disease. A systematic review of randomized clinical trials with meta-analysis.

    M. Shahien, A. Abdelhamed, M. Fahmy, H. Elkhodary, R. Salem, H. Samy, A. Elaraby (Shourok,Cairo, Egypt)

  • The epigenetic association of Parkinson’s disease risk gene- GPNMB rs199347 with drinking

    YC. Chen, SL. Wu, YP. Liaw (Changhua, Taiwan)

  • The examination of the relationship between limited thoracic mobility and shoulder joint function in individuals with extrapyramidal syndrome

    C. Bouzineki, A. Christakou, S. Kanellopoulou, X. Arabatzi, V. Sakellari (Athens, Greece)

  • The feasibility and efficacy of speech therapy via video call in patients with Parkinson’s disease: a preliminary study

    HJ. Chang, J. Kim, KA. Woo, JY. Joo, S. Kim, S. Lee, B. Jin, HY. Jeon, B. Jeon, HJ. Kim (Daejeon, Republic of Korea)

  • The feasibility of MRI guided focused ultrasound for posttraumatic tremor with prior hemicraniotomy and skull defect

    J. Maamary, J. Peters, Y. Barnett, B. Jonker, S. Tisch (Darlinghurst, Australia)

  • The Great Mimicker Strikes Again

    N. Schuck, K. Culpepper, A. Sethi, L. Terpak, J. Legacy (Jacksonville, USA)

  • The Healthy Brain Ageing (HeBA) Parkinson’s disease risk survey: Study design and methods

    C. Horlings, A. Garrido, C. Vega Moreno, S. Schade, T. Marques, P. Mahlknecht, C. Gomes, S. Ghosh, K. Rege, R. Rawal, C. Pauly, D. Mcintyre, K. Marini, K. Seppi, M. Marti, C. Trenkwalder, E. Tolosa, W. Poewe, V. Satagopam, R. Krüger, B. Mollenhauer (Innsbruck, Austria)

  • The High Prevalence of Developmental Vascular Anomalies in Parkinson’s Disease using USPIO-based MICRO MRI

    S. Sharma, S. Buch, D. Reese, T. Wade, G. Prado Miranda, M. Haacke, C. Tzoulis, M. Jog (London, Canada)

  • The hypometabolism in anterior cingulate gyrus and thalamus: potential biomarkers of disease progression in progressive supranuclear palsy

    B. Wang, H. Wang (Hangzhou, China)

  • The impact of anxiety symptoms and treatment on Parkinson’s disease-related disability: findings from the Parkinson’s Progression Markers Initiative

    N. Dahodwala, D. Weintraub, M. Bock, R. Cho, C. Caspell-Garcia, E. Brown, R. Dobkin (Philadelphia, USA)

  • The impact of biographic factors and lifestyle on the symptoms of Parkinson’s Disease – a five year follow-up

    J. Stögbauer, A. Bär, L. Schappe, U. Hillmann, K. Fassbender, C. Dupeyrat, D. Martens, J. Spiegel (Homburg, Germany)

  • The Impact of Diabetes Mellitus on Motor and Non-Motor Symptoms of Parkinson’s Disease: A Cross-Sectional Study.

    IC. Rodriguez-Gonzalez, F. Botello-Villagrana, SR. Gomez-Villalobos, A. Gonzalez-Cantu, X. Torres-Mancilla, M. Gonzalez-Gonzalez, D. Martinez-Ramirez (Monterrey, Mexico)

  • The impact of mild cognitive impairment on functioning in people with Parkinson’s disease

    J. Petrillo, TM. Brown, K. Paumier, J. Dine, R. Sawant, S. Baradaran, A. Koenig (Cambridge, USA)

  • The impact of STN-DBS on brain metabolic activity during dynamic obstacle avoidance in Parkinson’s disease

    I. Hanafi, C. Palmisano, G. Marotta, J. Delvecchio Delvecchio, G. Pezzoli, J. Volkmann, A. Buck, N. Pozzi, I. Isaias (Würzburg, Germany)

  • The impact of wearing ‘OFF’ (WO) episodes on non-motor symptoms (NMS) burden and quality of life (QoL) in Parkinson’s disease (PD) patients

    P. Nasuti, A. Brailean, W. Ali, A. Gillespie, C. Vandeloo, M. Biagioni (Brussels, Belgium)

  • The impact on religiosity following Deep Brain Stimulation (DBS) in patients with Essential Tremor (ET) and Parkinson’s Disease (PD)

    J. Frey, J. Lobo Lopes, M. Wajid, L. Kugler, C. Hess (Morgantown, USA)

  • The incidence of Parkinson’s disease in Nigeria: a systematic review and meta-analysis

    A. Memudu, E. Ekhoye (Iyamho, Nigeria)

  • The induction of mitochondrial damage by alpha synuclein In Parkinson’s disease.

    B. Adebisi (osogbo, Nigeria)

  • The investigation of a novel video game for identifying mild cognitive impairment in individuals with Parkinson’s disease

    K. Carey, G. Postma, B. Trokthi, C. Maitland (Corinth, USA)

  • The Link between Handedness and Prevalence of Musician’s Dystonia – A Systematic Literature Review

    S. Ouennane, S. Alici, M. Tiihonen, M. Butz (Duesseldorf, Germany)

  • The Link between Handedness and Prevalence of Writer’s Cramp – A Systematic Literature Review

    S. Alici, S. Ouennane, M. Tiihonen, M. Butz (Duesseldorf, Germany)

  • The long and short of contemporary parkinsonism survival: A 47-year clinicopathological study

    E. Noyes, AH. Rajput, A. Rajput (Saskatoon, Canada)

  • The mGlu2 positive allosteric modulator AZD8529 alleviates L-DOPA-induced dyskinesia and psychosis-like behaviours in the parkinsonian marmoset

    J. Shaqfah, I. Frouni, C. Kwan, D. Bédard, S. Nuara, J. Gourdon, A. Hamadjida, P. Huot (Montreal, Canada)

  • The monoamine oxidase-B inhibitor selegiline does not affect 18F-Florzolotau uptake in patients with progressive supranuclear palsy: a longitudinal case series

    XY. Li, TC. Yen, CT. Zuo, JW. Wang, JY. Lu, FT. Liu (Shanghai, China)

  • The N6-Methyladenosine mRNA Methylase METTL14 Regulates TLR4-mediated intestinal dysfunction in Parkinson’s Disease

    J. Zou, Z. Deng, ZZ. Lu, L. Wei, LL. Wu, F. Yu (Guangzhou, China)

  • The natural history of Parkinson’s disease in LRRK2 G2019S carriers

    M. Kmiecik, D. Coker, K. Heilbron, S. Aslibekyan, J. Shelton, P. Cannon, L. Norcliffe-Kaufmann (Sunnyvale, USA)

  • The neurological manifestations of PHARC syndrome: a systematic review

    V. Mendes Ferreira, M. Magriço, P. Bugalho, B. Meira, R. Barbosa (Lisboa, Portugal)

  • The neuroprotective miRNA family hsa-miR-451 has a distinctive pattern of downregulation in neurodegenerative diseases.

    R. Singh, V. Swarup, I. Ahmad, V. Anand, I. Singh, M. Faruq, A. Srivastava (New Delhi, India)

  • The neuroprotective properties of NLX-112 in MPTP treated mice are mediated by reactive gliosis and astrocytic GDNF

    W. Powell, A. Newman-Tancredi, L. Annett, R. Depoortere, M. Iravani (Hatfield, United Kingdom)

  • The Pain in Dystonia Scale (PIDS): Development and Validation

    V. Bruno, B. Achen, F. Francesca, R. Erro, S. Fox, M. Edwards, A. Schrag, M. Stamelou, S. Appel-Cresswell, G. Defazio, K. Ray Chaudhur, S. Pirio Richardson, H. Jinnah, D. Martino (Calgary, Canada)

  • The Parkinson’s Disease Composite of Executive-Functioning (PaCEF): A measure for detecting cognitive decline for Parkinson’s disease clinical trials

    C. Young, B. Cholerton, M. Shahid, C. Abdelnour, C. Zabetian, T. Montine, K. Poston (Stanford, USA)

  • The PD-Ballet study: a randomised controlled, single-blinded trial of dance therapy for Parkinson’s, baseline characteristics of the study cohort

    A. Podlewska, L. Batzu, J. Staunton, P. Tall, V. Leta, M. Uribe Mz-Recaman, F. Derbyshire-Fox, A. Hartley, T. Soukup, R. Davis, N. Sevdalis, A. Healey, I. Bakolis, C. Pariante, A. Woods, K. Ray Chaudhuri (London, United Kingdom)

  • The phenotypic landscape and genetic profile of movement disorders in a cohort of tunisian children

    M. Essid, H. Benrhouma, T. Benyounes, H. Klaa, R. Maroofian, Z. Miladi, I. Kraoua, H. Houlden, I. Ben Youssef-Turki (Tunis, Tunisia)

  • The phenotypic spectrum and assessment of severity in patients of Spinocerebellar Ataxia-12.

    V. Mathur, A. Shetty, P. Wadia (Jaipur, India)

  • The Pistol Sign

    S H. Wimalaratna (Oxford, United Kingdom)

  • The pivotal difference in gut microbiota between multiple system atrophy and Parkinson’s disease

    SY. Cheng, MC. Kuo, YF. Tseng (Taipei, Taiwan)

  • The pivotal role of dual tracer (FDG + DOPA) PET MRI brain for diagnosis of MSA-C.

    A. Mishra, D. Chaudhari (New Delhi, India)

  • The predictive potential of circular walking in prodromal Parkinson’s disease

    ME. Micó-Amigo, I. Kingma, S. Heinzel, S. Solbrig, MA. Hobert, M. Elshehabi, K. Brockmann, FG. Metzger, R. van Lummel, D. Berg, W. Maetzler, JH. van Dieen (Edinburgh, United Kingdom)

  • The prevalence and characteristics of REM sleep behavior disorder in progressive supranuclear palsy patients.

    APH. Phoumindr, JSR. Srignean, RBH. Bhidayasiri (Bangkok, Thailand)

  • The prevalence and clinical features of GBA-related Parkinson’s disease in a Slovak patient cohort

    A. Lackova, J. Necpal, V. Han, P. Pavelekova, K. Kulcsarova, T. Svorenova, L. Baranova, E. Tusay, B. Kovacova, E. Petro, B. Stasko, K. Burasova, M. Ostrozovicova, S. Bohacova, Z. Gdovinova, M. Skorvanek (Kosice, Slovakia)

  • The prevalence of delirium and subsequent outcomes in inpatients with Parkinson’s disease

    F. Gerakios, G. Bate, L. Wright, D. Davis, B. Stephan, L. Robinson, C. Brayne, L. Barnes, G. Stebbins, JP. Taylor, D. Burn, L. Allan, A. Yarnall, S. Richardson, R. Lawson (Newcastle Upon Tyne, United Kingdom)

  • The prevalence of Parkinson’s disease in a predominantly rural area of North West England

    R. Varden, R. Walker, A. O'Callaghan (Carlilse, United Kingdom)

  • The Prevalence of Primary Tauopathies in Ireland; a Clinically-Defined Study in the Province of Leinster: design and initial data.

    S. Lyons, R. Walsh, T. Lynch, S. O'Dowd (Dublin 24, Ireland)

  • The Quebec Parkinson Network (QPN): Interdisciplinary Collaboration in Parkinson’s Disease and Related Disorders Research.

    M. Blais, S. Bogard, C. Degroot, N. Dupré, E. Fon (Quebec City, Canada)

  • The Roche ‘End-to-End Matrix’ for Patient-Centric Drug Discovery and Development – Focus on Parkinson’s disease

    A. Paehler, A. Stepan, E. Mracsko, K. Taylor, B. Zinnhardt, H. Binch, L. Gobbi, T. Luebbers, A. Olivares, R. Rodriguez Sarmiento, U. Grether, S. Dudal, G. Pagano (Basel, Switzerland)

  • The Role of Adaptive Immunity caused by α-synuclein Recognition Specific Sequence Peptide on the Onset of Parkinson’s Disease Pathogenesis

    MG. Jo, BN. Lee, HM. Seong, SH. Kim, HN. Choi, MG. Kim, SP. Yun (Jinju, Republic of Korea)

  • The role of Anti-Ribosomal P antibody in Autoimmune cerebellar ataxia

    V. Vysakha (Trivandrum, India)

  • The role of depression in the development of Impulse Control Disorders in Parkinson´s Disease.

    M. Vales Montero, F. Ferre Navarrete, J. Conejo Galindo, P. Melgarejo Otálora, P. Andrés Camarón, J. Suárez Campayo, R. Reyes Marrero, JR. López-Trabada Gómez, MB. Díaz Rodríguez, F. Grandas (Madrid, Spain)

  • The role of genetic factors in the occurrence of levodopa-induced motor complications in Parkinson’s disease

    B. Radojević, N. Dragašević-Mišković, A. Milovanović, I. Petrović, M. Svetel, I. Jančić, D. Stanisavljević, O. Milićević, M. Savić, V. Kostić (Belgrade, Serbia)

  • The role of genetic testing in Dystonia diagnosis

    C. Guedes Vaz, J. Moura, D. Costa, A. Sardoeira, M. Magalhães (Porto, Portugal)

  • The role of RNA-carrying exosomes in synaptic physiology and in synucleinopathies

    A. Chopra, T. Outeiro (Göttingen, Germany)

  • The role of structural changes in the retina and the vertical vestibulo-ocular reflex abnormality in gait disorders in Parkinson`s disease

    O. Alenikova, O. Davydova, N. Alenikov (Minsk, Belarus)

  • The role of the default mode network and striatal circuits in the expression of depressive symptoms in premanifest Huntington’s disease

    T. Barta, L. Novelli, N. Georgiou-Karistianis, J. Stout, S. Loi, Y. Glikmann-Johnston, A. Razi (Clayton, Australia)

  • The role of the glymphatic system on the severity and distribution of alpha-synuclein pathology in alpha-synuclein fibril induced rat model of Parkinson’s disease

    E. Gök Dursun, M. Karataş, M. çetinkaya, K. Karlı Oğuz, B. Tel, G. Yalçın çakmaklı, B. Elibol (Ankara, Turkey)

  • The Short Duration Response and Long Duration Response to L-Dopa are Needed to Restore Vigor-Motivation Coupling in Parkinson Disease

    J. Brissenden, T. Scerbak, R. Albin, T. Lee (Ann Arbor, USA)

  • The significance of myocardial infarction as a developmental factor in parkinsonism and vascular parkinsonism

    DT. Akramova, GS. Rakhimbaeva (Tashkent, Uzbekistan)

  • The spatial and spectral organization of thalamo-cortical connectivity in patients with essential tremor

    A. Steina, S. Schnitzler, J. Vesper, E. Florin, A. Schnitzler, J. Hirschmann (Düsseldorf, Germany)

  • The specific application of a motor rehabilitation package in correcting the psycho-emotional sphere in patients with Parkinson’s disease.

    N. Voloshyna, I. Bogdanova, I. Voloshyn-Haponov (Kharkiv, Ukraine)

  • The spectrum of GBA mutations in the Korean population with Parkinson’s disease

    J. Hwangbo, J. Lee, SC. Cheon, KS. Park (Yangsan, Republic of Korea)

  • The study of genetic factors in levodopa-induced motor complications development in Russian patients with Parkinson’s disease

    G. Akhmadeeva, I. Khidiyatova, I. Gilyazova, S. Umutbaev, R. Galimova, A. Baitimerov, R. Magzhanov (Ufa, Russian Federation)

  • The Synuclein-One Study: Detection of Cutaneous Phosphorylated alpha-synuclein for the Diagnosis of the Synucleinopathies

    R. Freeman, T. Levine, J. Stohl, B. Bellaire, C. Gibbons (BOSTON, USA)

  • The use of contrast-enhanced ultrasonography of muscle spasticity and myofascial trigger points

    R. Bubnov (Kyiv, Ukraine)

  • The use of pallidal deep brain stimulation (GPi-DBS) to treat GNAO1 gene associated hyperkinetic syndromes

    A. Costa, D. Oliveira, M. Malaquias, L. Botelho, C. Silva, E. Cunha, V. Sá Pinto, N. Vila-Chã, I. Carrilho, M. Magalhães, A. Mendes (Porto, Portugal)

  • The Value of Physician Assistant/Associates (PAs) in a Movement Disorder Clinic

    J. Karl, C. Cooper (Chicago, USA)

  • The value of volume of the subthalamic nucleus in diagnosis of progressive supranuclear palsy

    JH. Ahn, JS. Lee, J. Youn, JW. Cho, EY. Kim (Seoul, Republic of Korea)

  • Theoretical Definition of DBS Electrode Misplacement

    I. Cruz, M. Wilken, S. Castillo-Torres, D. Cerquetti, M. Merello (Buenos Aires, Argentina)

  • Therapeutic effects of citral nanoliposome on Parkinson’s treatment in a rat model: Modulation via neurochemical, inflammatory and antioxidant pathways

    N. Moradikor, M. Haghipanah, W. Mohamed (Tbilisi, Georgia)

  • Therapeutic Plasma Exchange in the Management and Outcome of Stiff-Person Syndrome: A Systematic Review

    SK. Kharel, SS. Shrestha, SA. Acharya (Kathmandu, Nepal)

  • Therapy-associated risk decision making in individuals with multiple system atrophy and Parkinson’s disease, THE YAMSA TRIAL

    A. Bernhardt, M. Oeller, I. Friedrich, E. Kocakavuk, E. Nachman, K. Peikert, M. Roderigo, A. Rossmann, T. Schröter, LO. Wilhelm, F. Gandor, J. Levin, A. Giese, A. Janzen, WH. Oertel (Munich, Germany)

  • Thymoquinone and Edible Bird Nest: The Secret Ingredients to Protect Against MPTP-induced zebrafish Parkinson’s disease

    W. Mohamed (Kuantan, Malaysia)

  • Timed-up-and-go tests under dual-task conditions: Influence of different tasks on gait parameters in Parkinsonian patients

    C. Dupeyrat (HOMBURG, Germany)

  • To stimulate or not to stimulate? Bilateral subthalamic (STN) Deep Brain Stimulation (DBS) in cases of young-onset parkinsonism with mitochondrial dysfunction induced neurodegeneration.

    E. Efthymiou, B. Büchele, S. Mahendran, L. Stieglitz, C. Baumann, B. Balint (zurich, Switzerland)

  • Tongue fasciculations and numbness: A case of calcifying pseudoneoplasm

    S. Hudaib, N. Stubbs, L. Simon, V. Blake, E. Nduom, C. Branson (Atlanta, USA)

  • Topical Botulinum-Toxin-like Alternatives: A Systematic Literature Review

    S. Maytharakcheep, O. Phokaewvarangkul, R. Bhidayasiri (bangkok, Thailand)

  • Topography of cholinergic vulnerability correlates of PIGD motor deficits in DLB and PSP: A [18F]-FEOBV PET study

    P. Kanel, T. Brown, S. Roytman, J. Barr, C C. Spears, N. Bohnen (Ann Arbor, USA)

  • Touchscreen nQ application as a remote digital biomarker in Parkinson disease

    J. Yu, P. Gandara, O. Phillips, J. Liao, A. Holmes, I. Mondesire-Crump, J. Syrotenko, S. Mruthik, T. Arroyo-Gallego, H. Fernandez (Cleveland, USA)

  • Tourette Syndrome with Functional Overlay: A Diagnosis Challenge and The Role of Electrophysiological Study

    O. Udomsirithamrong, R. Bhidayasiri, P. Panyakeaw (Bangkok, Thailand)

  • Tourettism occurring during gender transition with testosterone therapy

    C. Comet, G. Haarman, E. Elowe-Gruau, A. Merglen, P. Burkhard, V. Fleury (Brussels, Belgium)

  • Towards smart glasses for improved care of individuals with Parkinson’s disease

    I. Kiprijanovska, F. Panchevski, S. Stankoski, M. Gjoreski, J. Archer, J. Broulidakis, I. Mavridou, B. Hayes, T. Guerreiro, C. Nduka, H. Gjoreski (Brighton, United Kingdom)

  • Training an APRN in movement disorders: lessons learned

    M. Burnett, A. Guggenmos (Omaha, USA)

  • Trajectories of Physical Performance in Prodromal and Early Parkinson’s Disease

    M. Bock, K. Covinsky, E. Vittinghoff, C. Tanner, K. Yaffe (San Francisco, USA)

  • Trajectories of Tardive Dyskinesia Impact Scale (TDIS) and Abnormal Involuntary Movement Scale (AIMS) over time with valbenazine treatment

    M. Perez-Rodriguez, D. Stull, R. Dhanda, M. Bron, E. Dunayevich, C. Correll (New York, USA)

  • Tramadol Induces Neuroinflammation, Mitochondrial Oxidative Stress, Neurotransmitters Dysbalanced and Produced Parkinson’s Disease Like Symptoms in Experimental Wistar Rats

    KHA. Aran (Moga, India)

  • Transcranial magnetic stimulation study in primary dystonia of presumed genetic etiology

    D. Dhar, A. Bhattacharya, N. Kamble, V. Holla, R. Yadav, B. Muthusamy, P. Pal (Bengaluru, India)

  • Transcranical Pulse Stimulation in Parkinson’s rest tremor: a pilot study.

    P. Manganotti, M. Liccari, TMI. Lombardo, M. Michelutti, M. Catalan (Trieste, Italy)

  • Transcriptional dysregulation in iPSC-derived neurons from patients with X-linked dystonia-parkinsonism

    K. Grütz, A. Künstner, C. Klein, H. Busch, P. Seibler (Lübeck, Germany)

  • Transcriptome-microRNA correlation and the regulation of targeted gene expression in de novo Parkinson’s disease patients.

    KE. Choi, SY. Kim, J. Jang, I. Hwang, KW. Lee, JS. Kim (Seoul, Republic of Korea)

  • Transcriptomic profiling in DYT1 dystonia: unravelling pathogenic pathways.

    N. Setó-Salvia, S. Wrigley, P. Cullinane, J. Hamilton, C. Arber, U. Yaman, H. Houlden, D. Salih, TT. Warner (London, United Kingdom)

  • Transferrin as a possible CSF biomarker in neurodegenerative proteinopathies

    K. Mensikova, P. Kanovsky, K. Klicova, D. Konickova, S. Kurcova, M. Nevrly, P. Otruba, Z. Grambalova, M. Kaiserova, J. Zapletalova (Olomouc, Czech Republic)

  • transformation of essential tremor into Parkinson’s disease

    A. Mukhacheva, S. Staimets, N. Zhukova, YU. Lalov, I. Zhukova, L. Tkachenko, A. Agasheva, D. Novotniy (Omsk, Russian Federation)

  • Transforming Parkinson’s Care in Africa: community engagement and involvement activities

    N. Fothergill-Misbah, R. Walker (Newcastle Upon Tyne, United Kingdom)

  • Transition among HD-ISS stages as an endpoint in clinical trials for HD

    J. Mills, J. Long, J. Vaidya, S. Sathe, C. Sampaio, S. Tabrizi (Iowa City, USA)

  • Traveling through the telescope: a neuromuscular and a movement disorders reunion

    A. Fernandes, M. Pinto, C. Soares, L. Braz, M. Rosas (PESO DA RÉGUA, Portugal)

  • Treatment induced psychogenic movement disorders: a case series

    V. Palakuzhy, S. Anderson, N. Patel (Chicago, USA)

  • Treatment of chorea in pediatric subjects with pallidal and thalamic deep brain stimulation

    J. Maclean, A. Salisbury, J. Olaya, M. Liker, T. Sanger (Orange, USA)

  • TREM2 maintain microglial proliferation and α-syn accumulation in PD models via the PI3K-Akt pathway

    S. Yin, Y. Xia, F. Wan, L. Kou, T. Wang (Wuhan, China)

  • Tremor characteristics differentially respond to levodopa and subthalamic nucleus deep brain stimulation in Parkinson’s disease

    T. Wirth, F. Ferreira, N. Vijiaratnam, C. Girges, A. Pakzad, A. Roquemaurel, O. Sinani, J. Hyam, M. Hariz, L. Zrinzo, H. Akram, P. Limousin, T. Foltynie (Strasbourg, France)

  • Tremor characteristics in patients with chronic inflammatory demyelinating polyneuropathy

    G. Pallada, SEM. Ten Holter, F. Eftimov, RMA. de Bie, JM. Dijk, AF. van Rootselaar (Amsterdam, Netherlands)

  • Tremor in patients with chronic inflammatory demyelinating polyneuropathy: prevalence and severity

    G. Pallada, SEM. Ten Holter, F. Eftimov, RMA. de Bie, AF. van Rootselaar, JM. Dijk (Amsterdam, Netherlands)

  • Tremor Reduction Using DBS: Outcomes of a Real-world, Prospective, Multicenter Essential Tremor Registry

    G. Deuschl, G. Loret, N. Kovacs, M. Blázquez Estrada, F. Clement, J. Lee, P. Schuurman, S. Delvaux, L. Chen, R. Jain (Kiel, Germany)

  • Tremors and More: A Case Report of TBK1 Mutation and Electrophysiological Assessment

    B. Elahi (Maywood, USA)

  • Trends in the evaluation and management of constipation in patients with Parkinson disease

    L. Deuel, W. Wright, E. Houston (Burlington, USA)

  • Trial protocol: Randomized double blind controlled study to investigate disease modifying effect, safety and optimal dose of oral semaglutide tablet for patients with Parkinson’s disease (MOST-ABLE study)

    Y. Kimura, T. Koda, H. Kurakami, S. Sakamoto, K. Iwasaki, H. Mochizuki (Suita, Osaka, Japan)

  • Trial site factor in Parkinson’s disease (PD) diary non-compliance

    P. Reksoprodjo (Prague, Czech Republic)

  • Turning 360 degrees in standing – associations with perceived walking difficulties and comfortable gait speed in people with drug naïve/early Parkinson’s disease.

    MH. Nilsson, M. Lindh-Rengifo, E. Stomrud, O. Hansson, SB. Jonasson (Lund, Sweden)

  • turning alterations detected by mobile health technology in idiopathic rem sleep behavioral disorders

    C. Zatti, A. Pilotto, A. Rizzardi, M. Catania, L. Purin, M. Pasolini, C. Hansen, R. Romijnders, E. Schaeffer, A. Galbiati, L. Ferini Strambi, D. Berg, W. Maetzler, A. Padovani (Brescia, Italy)

  • Two Distinctive Anatomic Location in Brain Tumor Patients with Secondary Parkinsonism Manifestation: A Serial Case Report

    Y. Diansari, S. Marisdina (Palembang, Indonesia)

Jump to:  View All • a b c d e f g h i j k l m n o p q r s [t] u v w x y z

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Welcome to the MDS Abstracts Site
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley